Medtech gears up for a vintage acquisition year
Device deal making is back in a big way, despite the munificence of venture funds.
Boston Scientific’s next move
The cardiovascular specialist needs to buy its way to growth – and it has marked an interest in a handful of smaller companies.
Medtech’s haves and have-nots
Medtronic’s quarterly results yesterday might presage a recovery, and some groups are in dire need of one.
Zimmer ditches slow-growing business to refocus
And the move will shake up the orthopaedic robotics scene.
A beautiful autumn for Covid-19 test makers
Though orthopaedics companies have begun to recover from the second quarter’s horrors, it is clear that the third quarter belongs to the diagnostics specialists.
